company background image
TNYA

Tenaya Therapeutics NasdaqGS:TNYA Stock Report

Last Price

US$3.24

Market Cap

US$207.3m

7D

-5.3%

1Y

-74.7%

Updated

03 Feb, 2023

Data

Company Financials +

Tenaya Therapeutics, Inc.

NasdaqGS:TNYA Stock Report

Mkt Cap: US$207.3m

TNYA Stock Overview

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

TNYA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Tenaya Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tenaya Therapeutics
Historical stock prices
Current Share PriceUS$3.24
52 Week HighUS$16.17
52 Week LowUS$1.64
Beta0
1 Month Change60.40%
3 Month Change67.88%
1 Year Change-74.71%
3 Year Changen/a
5 Year Changen/a
Change since IPO-78.89%

Recent News & Updates

Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Dec 06
Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment

Sep 06

Recent updates

Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Dec 06
Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment

Sep 06

Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07

Aug 10

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Nov 01
Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms

Aug 06

Shareholder Returns

TNYAUS BiotechsUS Market
7D-5.3%-0.8%2.9%
1Y-74.7%4.5%-8.5%

Return vs Industry: TNYA underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: TNYA underperformed the US Market which returned -9.1% over the past year.

Price Volatility

Is TNYA's price volatile compared to industry and market?
TNYA volatility
TNYA Average Weekly Movement17.8%
Biotechs Industry Average Movement12.2%
Market Average Movement6.8%
10% most volatile stocks in US Market17.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: TNYA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: TNYA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2016140Faraz Alihttps://www.tenayatherapeutics.com

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).

Tenaya Therapeutics, Inc. Fundamentals Summary

How do Tenaya Therapeutics's earnings and revenue compare to its market cap?
TNYA fundamental statistics
Market CapUS$207.32m
Earnings (TTM)-US$116.30m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TNYA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$116.30m
Earnings-US$116.30m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.82
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TNYA perform over the long term?

See historical performance and comparison